Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $22

Benzinga · 1d ago
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $24 to $22.